Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: HLA-G

Gene summary for HLA-G

Gene summary.

Gene information	Species	Human
	Gene symbol	HLA-G
	Gene ID	3135
	Gene name	major histocompatibility complex, class I, G
	Gene Alias	MHC-G
	Cytomap	6p22.1
	Gene Type	protein-coding
	GO ID	GO:0001525
	UniProtAcc	P17693

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
3135	HLA-G	sample1	Human	Cervix	CC	8.53e-38	8.96e-01	0.0959
3135	HLA-G	T1	Human	Cervix	CC	3.24e-45	7.60e-01	0.0918
3135	HLA-G	P1T-E	Human	Esophagus	ESCC	1.08e-09	7.81e-01	0.0875
3135	HLA-G	P2T-E	Human	Esophagus	ESCC	5.97e-19	2.99e-01	0.1177
3135	HLA-G	P11T-E	Human	Esophagus	ESCC	1.22e-06	2.58e-01	0.1426
3135	HLA-G	P17T-E	Human	Esophagus	ESCC	1.21e-04	2.92e-01	0.1278
3135	HLA-G	P21T-E	Human	Esophagus	ESCC	4.15e-02	8.81e-02	0.1617
3135	HLA-G	P37T-E	Human	Esophagus	ESCC	9.10e-10	1.62e-01	0.1371
3135	HLA-G	P44T-E	Human	Esophagus	ESCC	6.80e-04	1.91e-01	0.1096
3135	HLA-G	P49T-E	Human	Esophagus	ESCC	2.04e-02	2.09e-01	0.1768
3135	HLA-G	P62T-E	Human	Esophagus	ESCC	1.01e-05	9.33e-02	0.1302
3135	HLA-G	P75T-E	Human	Esophagus	ESCC	6.52e-11	2.38e-01	0.1125
3135	HLA-G	P79T-E	Human	Esophagus	ESCC	4.89e-06	1.18e-01	0.1154
3135	HLA-G	P80T-E	Human	Esophagus	ESCC	5.23e-27	8.89e-01	0.155
3135	HLA-G	P83T-E	Human	Esophagus	ESCC	1.11e-21	5.59e-01	0.1738
3135	HLA-G	P94T-E	Human	Esophagus	ESCC	1.64e-05	8.55e-01	0.0879
3135	HLA-G	P104T-E	Human	Esophagus	ESCC	4.70e-09	1.64e+00	0.0931

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:002240710	Cervix	CC	regulation of cell-cell adhesion	103/2311	448/18723	1.78e-10	2.87e-08	103
GO:004578510	Cervix	CC	positive regulation of cell adhesion	101/2311	437/18723	1.96e-10	3.08e-08	101
GO:00421108	Cervix	CC	T cell activation	107/2311	487/18723	1.24e-09	1.46e-07	107
GO:00508638	Cervix	CC	regulation of T cell activation	80/2311	329/18723	1.28e-09	1.47e-07	80
GO:00321035	Cervix	CC	positive regulation of response to external stimulus	95/2311	427/18723	5.44e-09	5.03e-07	95
GO:00071598	Cervix	CC	leukocyte cell-cell adhesion	85/2311	371/18723	8.27e-09	7.07e-07	85
GO:00071626	Cervix	CC	negative regulation of cell adhesion	72/2311	303/18723	2.36e-08	1.70e-06	72
GO:00026837	Cervix	CC	negative regulation of immune system process	94/2311	434/18723	2.63e-08	1.87e-06	94
GO:19030378	Cervix	CC	regulation of leukocyte cell-cell adhesion	77/2311	336/18723	4.08e-08	2.54e-06	77
GO:004800210	Cervix	CC	antigen processing and presentation of peptide antigen	24/2311	62/18723	1.21e-07	6.07e-06	24
GO:00027644	Cervix	CC	immune response-regulating signaling pathway	97/2311	468/18723	1.49e-07	7.07e-06	97
GO:190370610	Cervix	CC	regulation of hemopoiesis	80/2311	367/18723	2.14e-07	9.55e-06	80
GO:00075689	Cervix	CC	aging	75/2311	339/18723	2.75e-07	1.13e-05	75
GO:00018197	Cervix	CC	positive regulation of cytokine production	95/2311	467/18723	4.88e-07	1.85e-05	95
GO:001988210	Cervix	CC	antigen processing and presentation	32/2311	106/18723	8.61e-07	3.08e-05	32
GO:00420988	Cervix	CC	T cell proliferation	49/2311	199/18723	1.32e-06	4.49e-05	49
GO:00224084	Cervix	CC	negative regulation of cell-cell adhesion	48/2311	196/18723	1.99e-06	6.18e-05	48
GO:000248310	Cervix	CC	antigen processing and presentation of endogenous peptide antigen	11/2311	19/18723	2.89e-06	8.23e-05	11
GO:00421297	Cervix	CC	regulation of T cell proliferation	43/2311	171/18723	3.21e-06	8.77e-05	43
GO:001988310	Cervix	CC	antigen processing and presentation of endogenous antigen	13/2311	26/18723	3.25e-06	8.80e-05	13

Page: 1 2 3 4 5 6 7

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0461220	Cervix	CC	Antigen processing and presentation	34/1267	78/8465	1.06e-09	2.14e-08	1.26e-08	34
hsa0516720	Cervix	CC	Kaposi sarcoma-associated herpesvirus infection	60/1267	194/8465	9.74e-09	1.58e-07	9.33e-08	60
hsa0516318	Cervix	CC	Human cytomegalovirus infection	65/1267	225/8465	4.59e-08	6.47e-07	3.83e-07	65
hsa0414520	Cervix	CC	Phagosome	47/1267	152/8465	3.95e-07	4.26e-06	2.52e-06	47
hsa0414418	Cervix	CC	Endocytosis	64/1267	251/8465	6.97e-06	6.10e-05	3.61e-05	64
hsa0517016	Cervix	CC	Human immunodeficiency virus 1 infection	55/1267	212/8465	1.80e-05	1.42e-04	8.40e-05	55
hsa04612110	Cervix	CC	Antigen processing and presentation	34/1267	78/8465	1.06e-09	2.14e-08	1.26e-08	34
hsa05167110	Cervix	CC	Kaposi sarcoma-associated herpesvirus infection	60/1267	194/8465	9.74e-09	1.58e-07	9.33e-08	60
hsa0516319	Cervix	CC	Human cytomegalovirus infection	65/1267	225/8465	4.59e-08	6.47e-07	3.83e-07	65
hsa04145110	Cervix	CC	Phagosome	47/1267	152/8465	3.95e-07	4.26e-06	2.52e-06	47
hsa0414419	Cervix	CC	Endocytosis	64/1267	251/8465	6.97e-06	6.10e-05	3.61e-05	64
hsa0517017	Cervix	CC	Human immunodeficiency virus 1 infection	55/1267	212/8465	1.80e-05	1.42e-04	8.40e-05	55
hsa04144210	Esophagus	ESCC	Endocytosis	186/4205	251/8465	9.74e-16	4.66e-14	2.39e-14	186
hsa05166211	Esophagus	ESCC	Human T-cell leukemia virus 1 infection	164/4205	222/8465	8.13e-14	2.09e-12	1.07e-12	164
hsa05169210	Esophagus	ESCC	Epstein-Barr virus infection	151/4205	202/8465	1.55e-13	3.45e-12	1.77e-12	151
hsa0421829	Esophagus	ESCC	Cellular senescence	119/4205	156/8465	5.89e-12	9.40e-11	4.81e-11	119
hsa05170210	Esophagus	ESCC	Human immunodeficiency virus 1 infection	147/4205	212/8465	3.37e-09	3.53e-08	1.81e-08	147
hsa05167211	Esophagus	ESCC	Kaposi sarcoma-associated herpesvirus infection	136/4205	194/8465	4.28e-09	4.22e-08	2.16e-08	136
hsa0516510	Esophagus	ESCC	Human papillomavirus infection	215/4205	331/8465	7.86e-09	7.12e-08	3.65e-08	215
hsa05163210	Esophagus	ESCC	Human cytomegalovirus infection	148/4205	225/8465	5.73e-07	4.00e-06	2.05e-06	148

Page: 1 2

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

HLA-G

SNV

Missense_Mutation

c.648C>A

p.His216Gln

p.H216Q

P17693

protein_coding

deleterious_low_confidence(0)

benign(0.031)

TCGA-A8-A07L-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

HLA-G

SNV

Missense_Mutation

rs767964419

c.593A>G

p.Asn198Ser

p.N198S

P17693

protein_coding

deleterious_low_confidence(0.04)

probably_damaging(0.982)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

HLA-G

SNV

Missense_Mutation

novel

c.733N>A

p.Gly245Arg

p.G245R

P17693

protein_coding

deleterious_low_confidence(0.02)

probably_damaging(1)

TCGA-AN-A0XW-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

HLA-G

insertion

Nonsense_Mutation

novel

c.68_69insCTTAAGAGCTTTGTGAGTCCTGTT

p.Trp23delinsCysLeuArgAlaLeuTerValLeuLeu

p.W23delinsCLRAL*VLL

P17693

protein_coding

TCGA-A8-A07I-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

5-fluorouracil

HLA-G

SNV

Missense_Mutation

novel

c.532N>A

p.Glu178Lys

p.E178K

P17693

protein_coding

deleterious_low_confidence(0.03)

probably_damaging(0.997)

TCGA-DS-A7WH-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

HLA-G

SNV

Missense_Mutation

c.256N>C

p.Glu86Gln

p.E86Q

P17693

protein_coding

tolerated_low_confidence(0.32)

benign(0.006)

TCGA-IR-A3LF-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

HLA-G

SNV

Missense_Mutation

c.258N>T

p.Glu86Asp

p.E86D

P17693

protein_coding

tolerated_low_confidence(0.09)

benign(0.027)

TCGA-AA-3815-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

HLA-G

SNV

Missense_Mutation

c.910N>T

p.Pro304Ser

p.P304S

P17693

protein_coding

tolerated_low_confidence(0.66)

possibly_damaging(0.506)

TCGA-AA-3966-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

HLA-G

SNV

Missense_Mutation

c.391N>A

p.Gly131Arg

p.G131R

P17693

protein_coding

deleterious_low_confidence(0.04)

probably_damaging(0.997)

TCGA-AD-6889-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Chemotherapy

xeloda

HLA-G

SNV

Missense_Mutation

rs780775783

c.316N>T

p.Arg106Cys

p.R106C

P17693

protein_coding

deleterious_low_confidence(0.01)

probably_damaging(0.925)

TCGA-AY-6197-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
3135	HLA-G	EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME		hmg coa reductase inhibitors
3135	HLA-G	EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME		fluorouracil	FLUOROURACIL
3135	HLA-G	EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME		methotrexate	METHOTREXATE	16906016,19088262
3135	HLA-G	EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME		capecitabine	CAPECITABINE

Page: 1